Burning Rock Biotech
BNR
54 hedge funds and large institutions have $635M invested in Burning Rock Biotech in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 16 closing their positions.
34% more capital invested
Capital invested by funds: $474M → $635M (+$161M)
0.33% more ownership
Funds ownership: 2.37% → 2.7% (+0.33%)
7% less funds holding
Funds holding: 58 → 54 (-4)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$152M |
| 2 |
Goldman Sachs
New York
|
+$20.9M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$20.7M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$14.1M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$68.9M |
| 2 |
CC
Casdin Capital
New York
|
-$32.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.3M |
| 4 |
AMH
Aspex Management (HK)
Central,
Hong Kong
|
-$11.2M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$10.4M |
BNR Hedge Fund Activity: Q1 2021 in Review
54 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q1 2021, worth a combined $635M — up 34% from $474M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BNR and 13 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $152M. The largest seller was OrbiMed, cutting an estimated $68.9M.
- 54 institutional investors held Burning Rock Biotech (BNR) as of Q1 2021, down from 58 in Q4 2020.
- Funds reported $635M of Burning Rock Biotech stock for Q1 2021, up 34% quarter-over-quarter.
- 13 funds opened new Burning Rock Biotech positions in Q1 2021 and 16 closed out, a net change of -3 holders.
- The largest Burning Rock Biotech buyer in Q1 2021 was Baillie Gifford & Co, an estimated $152M added.
- The largest Burning Rock Biotech seller in Q1 2021 was OrbiMed, an estimated $68.9M sold.
Based on aggregated 13F filings for Q1 2021.